^
CANCER:

Cholangiocarcinoma

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
FGFR2 rearrangement
Cholangiocarcinoma
pemigatinib
Sensitive
:
A1
PRNewswire - 1 week - (New A1)
FGFR2 fusion
Cholangiocarcinoma
pemigatinib
Sensitive
:
A1
PRNewswire - 1 week - (New A1)
FGFR2 fusion
Cholangiocarcinoma
ARQ 087
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
FGFR2 amplification
Cholangiocarcinoma
ARQ 087
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
IDH1 R132C + PIK3CA E545K + IDH2 R172K
Cholangiocarcinoma
ivosidenib
Resistant
:
C4
NPJ Precis Oncol - 3 weeks - (New C4)
FGFR2 M540_I541insMM
Cholangiocarcinoma
pemigatinib
Sensitive
:
C4
Target Oncol - 3 weeks - (New C4)
FGFR2 rearrangement
Cholangiocarcinoma
infigratinib
Sensitive
:
A1
FGFR2 fusion
Cholangiocarcinoma
infigratinib
Sensitive
:
A1
IDH1 mutation
Cholangiocarcinoma
ivosidenib
Sensitive
:
A1
No biomarker
Cholangiocarcinoma
gemcitabine + albumin-bound paclitaxel
Sensitive
:
A2
No biomarker
Cholangiocarcinoma
gemcitabine
Sensitive
:
A2
No biomarker
Cholangiocarcinoma
infigratinib
Sensitive
:
B
FGFR2 rearrangement
Cholangiocarcinoma
TAS 120
Sensitive
:
B
FGFR2 fusion
Cholangiocarcinoma
TAS 120
Sensitive
:
B
HER-2 expression
Cholangiocarcinoma
trastuzumab + lapatinib
Sensitive
:
B
No biomarker
Cholangiocarcinoma
TT-00420
Sensitive
:
B
RET fusion
Cholangiocarcinoma
pralsetinib
Sensitive
:
C1
BRCA2 mutation
Cholangiocarcinoma
olaparib
Sensitive
:
C1
BRCA1 mutation
Cholangiocarcinoma
olaparib
Sensitive
:
C1
FGFR3 mutation
Cholangiocarcinoma
erdafitinib
Sensitive
:
C1
FGFR2 mutation
Cholangiocarcinoma
erdafitinib
Sensitive
:
C1
NTRK3 fusion
Cholangiocarcinoma
larotrectinib
Sensitive
:
C1
NTRK2 fusion
Cholangiocarcinoma
larotrectinib
Sensitive
:
C1
NTRK1 fusion
Cholangiocarcinoma
larotrectinib
Sensitive
:
C1
BRAF V600
Cholangiocarcinoma
vemurafenib
Sensitive
:
C1
MSI-H/dMMR
Cholangiocarcinoma
pembrolizumab
Sensitive
:
C1
BRAF V600E
Cholangiocarcinoma
trametinib + dabrafenib
Sensitive
:
C1
NTRK2 fusion
Cholangiocarcinoma
entrectinib
Sensitive
:
C1
NTRK3 fusion
Cholangiocarcinoma
entrectinib
Sensitive
:
C1
NTRK1 fusion
Cholangiocarcinoma
entrectinib
Sensitive
:
C1
HER-2 overexpression
Cholangiocarcinoma
lapatinib
Sensitive
:
C1
BRAF V600E
Cholangiocarcinoma
vemurafenib
Sensitive
:
C1
FGFR2 translocation
Cholangiocarcinoma
pemigatinib
Sensitive
:
C2
FGFR2 mutation
Cholangiocarcinoma
infigratinib
Sensitive
:
C2
FGFR2 mutation
Cholangiocarcinoma
ARQ 087
Sensitive
:
C2
FGFR2 mutation
Cholangiocarcinoma
TAS 120
Sensitive
:
C2
IDH2 mutation
Cholangiocarcinoma
dasatinib
Sensitive
:
C2
IDH1 R132C
Cholangiocarcinoma
ivosidenib
Sensitive
:
C2